Sustainability Accounting Standards Board (SASB)

The Sustainability Accounting Standards Board (SASB) is dedicated to improving the effectiveness and comparability of corporate disclosure on environmental, social and governance (ESG) factors.

Resources

 

The table below cross-references the SASB Standards for the Health Care sector, and Biotechnology & Pharmaceuticals industry, with where that information can be found in conjunction with GRI disclosures throughout this report.

Index #Description Website
Safety of Clinical Trial Participants
210a.1 Management process for ensuring quality and patient safety during clinical trials globally Clinical Research

Product & Patient Safety
Quality & Safety Standards

Clinical Trials Website
210a.2 FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in:
(1) Voluntary Action Indicated (VAI) and
(2) Official Action Indicated (OAI)
Clinical Research

Clinical Trials Website
210a.3 Monetary losses as a result of legal proceedings associated with clinical trials in developing countries1 Not reported
Access to Medicines
240a.1Access to health care for priority diseases and in priority countries Access to Health
Enabling Access to Health
HIV/AIDS
Key Initiatives
Product Pricing
Product Donations
Product Registration
Vaccines
Women's Health
240a.2Products on WHO’s List of Prequalified Medicinal Products Product Registration
Affordability & Pricing
240b.1 Settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market Not reported
240b.2 Percentage change in: (1) average list price and
(2) average net price across U.S. product portfolio compared to previous year
Product Pricing
240b.3Percentage change in: (1) list price and
(2) net price of product with largest increase compared to previous year
Product Pricing
Drug Safety
250a.1Products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database We do not currently disclose this information. See links for related information.
 
FAERS MedWatch
250a.2 Fatalities associated with products as reported in the FDA Adverse Event Reporting System We do not currently disclose this information. See links for related information.
 
FAERS MedWatch
250a.3 Recalls issued, and total units recalled Quality & Safety Standards
FAERS MedWatch
250a.4Amount of product accepted for takeback, reuse, or disposal Not reported
250a.5FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP)2 Not reported
Counterfeit Drugs
260a.1 Methods and technologies used to maintain traceability of products throughout the supply chain Manufacturing & Supply
Quality & Safety Standards
Sourcing & Supplier Relations
260a.2 Process for alerting customers and business partners of potential or known risks associated with counterfeit products Not reported
260a.3Actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products Not reported
Ethical Marketing
270a.1 Monetary losses as a result of legal proceedings associated with false marketing claims1 Sales & Marketing Practices
270a.2 Code of ethics governing promotion of off-label use of products Sales & Marketing Practices
Sales and Marketing
Employee Recruitment, Development, and Retention
330a.1 Talent recruitment and retention efforts for R&D personnel Research & Development
MRL Postdoctoral Research Fellow Program
330a.2 (1) Voluntary and (2) involuntary turnover rate for:
(a) executives and senior managers, (b) midlevel managers,
(c) professionals, and (d) all others
Not reported. See our Global Diversity & Inclusion
page for related information.
Supply Chain Management
430a.1 Facilities and Tier I suppliers participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program, or equivalent Not reported
Business Ethics
510a.1Monetary losses as a result of legal proceedings associated with corruption and bribery Not reported
510a.2Code of ethics governing interactions with health care professionals Engaging With Health Care Professionals

Sales & Marketing Practices
Code of Conduct
Compliance
Sales and Marketing
Activity Metrics
000.APatients treated (#) Social Investments
000.BNumber of drugs (1) in portfolio and (2) in R&D (Phases 1-3) Pipeline
1 Note to HC-BP-210a.3 – The entity shall briefly describe the nature, context, and any corrective actions taken as a result of the monetary losses.
2 Note to HC-BP-250a.5 – The entity shall briefly describe the nature, context, and any corrective actions taken as a result of the enforcement actions.